PH12017501422A1 - 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders - Google Patents
1-heterocyclyl isochromanyl compounds and analogs for treating cns disordersInfo
- Publication number
- PH12017501422A1 PH12017501422A1 PH12017501422A PH12017501422A PH12017501422A1 PH 12017501422 A1 PH12017501422 A1 PH 12017501422A1 PH 12017501422 A PH12017501422 A PH 12017501422A PH 12017501422 A PH12017501422 A PH 12017501422A PH 12017501422 A1 PH12017501422 A1 PH 12017501422A1
- Authority
- PH
- Philippines
- Prior art keywords
- compounds
- isochromanyl
- heterocyclyl
- analogs
- cns disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 | |
| PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12017501422A1 true PH12017501422A1 (en) | 2018-03-19 |
Family
ID=55456908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017501422A PH12017501422A1 (en) | 2015-02-11 | 2017-08-09 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (enExample) |
| EP (2) | EP4046995B1 (enExample) |
| JP (3) | JP6657241B2 (enExample) |
| KR (1) | KR102601972B1 (enExample) |
| CN (2) | CN111925360B (enExample) |
| AU (1) | AU2016219253C1 (enExample) |
| CA (1) | CA2976095C (enExample) |
| CY (1) | CY1125198T1 (enExample) |
| DK (1) | DK3256466T3 (enExample) |
| EA (1) | EA201791804A1 (enExample) |
| ES (2) | ES2967643T3 (enExample) |
| HU (1) | HUE058698T2 (enExample) |
| IL (1) | IL253914B (enExample) |
| MX (2) | MX371404B (enExample) |
| MY (1) | MY188160A (enExample) |
| NZ (1) | NZ735011A (enExample) |
| PH (1) | PH12017501422A1 (enExample) |
| PL (1) | PL3256466T3 (enExample) |
| PT (1) | PT3256466T (enExample) |
| SG (2) | SG10201806809QA (enExample) |
| UA (1) | UA122222C2 (enExample) |
| WO (1) | WO2016130796A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016219253C1 (en) * | 2015-02-11 | 2022-12-08 | Pgi Drug Discovery Llc | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders |
| CA2976092A1 (en) * | 2015-02-11 | 2016-08-18 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
| MX2019000982A (es) | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
| EA201990400A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения и композиции и их применение |
| IL271464B2 (en) | 2017-06-30 | 2024-08-01 | Chase Therapeutics Corp | NK-1 antagonist compositions and methods for use in the treatment of depression |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| DE69912279T2 (de) | 1998-06-30 | 2004-07-29 | Eli Lilly And Co., Indianapolis | 5-ht1f agonisten |
| SE9902267D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| EP1446396A1 (en) * | 2001-11-08 | 2004-08-18 | Sepracor, Inc. | Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram |
| JP4738418B2 (ja) * | 2004-12-21 | 2011-08-03 | エフ．ホフマン−ラ ロシュ アーゲー | クロマン誘導体及びｃｎｓ障害の処置におけるその使用 |
| JP2008538576A (ja) | 2005-04-22 | 2008-10-30 | ワイス | クロマンおよびクロメン誘導体およびその使用 |
| JP2009524618A (ja) * | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置における２−イミダゾールの使用 |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| PT3252057T (pt) | 2009-12-04 | 2024-06-04 | Sunovion Pharmaceuticals Inc | Compostos multicíclicos e métodos de utilização dos mesmos |
| JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| AR090557A1 (es) | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| AU2013369649B2 (en) * | 2012-12-31 | 2018-07-26 | Sunovion Pharmaceuticals Inc. | Heterocyclic compounds and methods of use thereof |
| AU2016219253C1 (en) * | 2015-02-11 | 2022-12-08 | Pgi Drug Discovery Llc | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders |
-
2016
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en not_active Ceased
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en not_active IP Right Cessation
- 2016-02-11 MX MX2020001157A patent/MX392664B/es unknown
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active Active
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en not_active Ceased
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh not_active Expired - Fee Related
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh not_active Expired - Fee Related
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja not_active Expired - Fee Related
- 2016-02-11 US US15/041,852 patent/US9856238B2/en not_active Expired - Fee Related
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en not_active Expired - Fee Related
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja not_active Expired - Fee Related
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en not_active Abandoned
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
- 2022-05-20 CY CY20221100352T patent/CY1125198T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ735011A (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| PH12017501423A1 (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| MY194002A (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| PH12019500432B1 (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| PH12015501962A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| MX2022005024A (es) | Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc). | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |